Evidence map›Paper›PMID 33522249›Full record

Trial reportJournal of the American Heart Association2021

Clinical Characteristics and Outcomes of Patients With Heart Failure With Reduced Ejection Fraction and Chronic Obstructive Pulmonary Disease: Insights From PARADIGM-HF.

Solmaz Ehteshami-Afshar, Leanne Mooney, Pooja Dewan, Akshay S Desai, Ninian N Lang, Martin P Lefkowitz, Mark C Petrie, Adel R Rizkala, Jean L Rouleau, Scott D Solomon and 7 more

Open access · goldAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of the American Heart Association, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 2 pooled it
5.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 2 syntheses or guidelines pooled it, 48 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Observational
  8. Article
  9. Review
  10. A Proposed Checklist for Optimizing COPD Patient Discharge Processes in Italian Internal Medicine Wards.International journal of chronic obstructive pulmonary disease · 2026
    Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Diagnosis and management of comorbid disease in COPD.Breathe (Sheffield, England) · 2025
    Review
  20. Biomarkers in COPD-Associated PH/CCP: Circulating Molecules and Cell-Intrinsic Marker.International journal of chronic obstructive pulmonary disease · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 9 institutions in 4 countries.

Solmaz Ehteshami-AfsharDepartment of Medicine Yale University School of Medicine New Haven CT.
Leanne MooneyBHF Glasgow Cardiovascular Research Centre University of Glasgow Glasgow UK.
Pooja DewanBHF Glasgow Cardiovascular Research Centre University of Glasgow Glasgow UK.
Akshay S DesaiDivision of Cardiovascular Medicine Brigham and Women's Hospital Boston MA.
Ninian N LangBHF Glasgow Cardiovascular Research Centre University of Glasgow Glasgow UK.
Martin P LefkowitzNovartis Pharmaceutical Corporation East Hanover NJ.
Mark C PetrieBHF Glasgow Cardiovascular Research Centre University of Glasgow Glasgow UK.
Adel R RizkalaNovartis Pharmaceutical Corporation East Hanover NJ.
Jean L RouleauInstitut de Cardiologie Université de Montréal Montréal Québec Canada.
Scott D SolomonDivision of Cardiovascular Medicine Brigham and Women's Hospital Boston MA.
Karl SwedbergUniversity of Gothenburg Gothenburg Sweden.
Victor C ShiNovartis Pharmaceutical Corporation East Hanover NJ.
Michael R ZileDepartment of Medicine Medical University of South Carolina Charleston SC.
Milton PackerBaylor Heart and Vascular InstituteBaylor University Medical CenterImperial College Dallas TX USA.
John J V McMurrayBHF Glasgow Cardiovascular Research Centre University of Glasgow Glasgow UK.
Pardeep S JhundBHF Glasgow Cardiovascular Research Centre University of Glasgow Glasgow UK.
Nathaniel M HawkinsDivision of Cardiology University of British Columbia Vancouver Canada.
University of Glasgow · GBNovartis (United States) · USBrigham and Women's Hospital · USBaylor University Medical Center · USMedical University of South Carolina · USMontreal Heart Institute · CAUniversity of British Columbia · CAUniversity of Gothenburg · SEYale University · US

Funding

British Heart Foundation RE/18/6/34217
6 · The paper itself

Abstract

Background Chronic obstructive pulmonary disease (COPD) is a common comorbidity in heart failure with reduced ejection fraction, associated with undertreatment and worse outcomes. New treatments for heart failure with reduced ejection fraction may be particularly important in patients with concomitant COPD. Methods and Results We examined outcomes in 8399 patients with heart failure with reduced ejection fraction, according to COPD status, in the PARADIGM-HF (Prospective Comparison of Angiotensin Receptor Blocker-Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure) trial. Cox regression models were used to compare COPD versus non-COPD subgroups and the effects of sacubitril/valsartan versus enalapril. Patients with COPD (n=1080, 12.9%) were older than patients without COPD (mean 67 versus 63 years;

Indexed as

AgedAminobutyratesAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsBiomarkersBiphenyl CompoundsDose-Response Relationship, DrugDouble-Blind MethodDrug Administration ScheduleDrug CombinationsEnalaprilFemaleFollow-Up StudiesHeart FailureHospitalizationHumansAminobutyratesAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsBiomarkersBiphenyl CompoundsDrug CombinationsEnalaprilNatriuretic Peptide, BrainPeptide Fragmentspro-brain natriuretic peptide (1-76)sacubitril and valsartan sodium hydrate drug combinationValsartanchronic obstructive pulmonary diseaseejection fractionheart failurehospitalizationmortalityneprilysinright ventricle

Identifiers

PMID33522249
PMCPMC7955331
OpenAlexW3129156895

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.